Dunedin hospital construction timeline revealed
A six-month job capping piles and pouring concrete will kick off the resumption of work this month on the new Dunedin Hospital inpatient building.
Health Minister Simeon Brown announced the work this afternoon after the Otago Daily Times earlier revealed a letter of intent to build the project had been signed with Australian construction giant CPB.
The agreement followed years of fraught negotiations and government dithering.
Mr Brown also announced the formation of a local engagement group to "strengthen communication with the local community".
The group would bring together Health New Zealand leaders and local stakeholders, including representatives from local government, infrastructure partners, and tertiary institutions.
It would not provide advice on "the building's design scope, clinical models of care, or procurement decisions".
The early construction phase would see 134 pile caps installed, made from steel-reinforced concrete, Mr Brown said in a statement.
Around 4,300 cubic metres of concrete will be poured across the site, with approximately 490 tonnes of reinforcing steel used in total.
'This work will take about six months and includes detailed inspections of every pile to ensure the facility is built to the highest design and safety standards.'
The next major construction phase was the substructure expected to begin in early 2026.
'This phase will prepare the site for base isolators and IL4 foundations – ensuring the hospital can keep functioning after a major earthquake or natural disaster. That's essential for the people of Dunedin and the wider region.'
The 70,000 square metre inpatient building is due to open in 2031.
Timeline
July 2025 – January 2026 (6 months): Pile caps and remedial works
January 2026 – July 2026 (6 months): Substructure works, including installation of lower slab, concreting, and plinths for base isolators
July 2026: Base isolators installed
August 2026: Steel structure construction commences - APL
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scoop
3 hours ago
- Scoop
Global Review Finds Mediterranean Diet May Play Key Role In Managing ADHD
It's the superhero of the nutrition world, and now a scientific review has shown the potential power of the Mediterranean diet to help manage the symptoms of Attention Deficit/Hyperactivity Disorder. The recently published review by the University of the Sunshine Coast is one of the first to directly research the benefits of the Mediterranean diet – with its high intake of fruits, vegetables, wholegrains and extra-virgin olive oil – versus unhealthy diets typically high in sugar, additives and saturated fats, to lessen ADHD symptoms. UniSC Psychology researcher Naomi Lewis said the novel review examined all available global evidence on the key nutrients and dietary patterns implicated in ADHD, and linked the findings to underlying biological mechanisms such as gut imbalance and inflammation. 'We found strong evidence that diet and nutrition may be more important than we think when it comes to managing ADHD symptoms and providing protective benefits,' she said. The study builds on earlier findings by the researchers on the role of diet in brain-gut inflammation pathways in ADHD, that an imbalance of good versus bad gut microorganisms may impact the severity of symptoms. 'What we eat plays a big role in the health of our gut microbiome, which are the trillions of bacteria and other microbes in our digestive system that help support brain and overall health,' Ms Lewis said. 'When these microbes become imbalanced, it can affect our physical and mental wellbeing, including possibly making symptoms of ADHD worse. This is because an imbalanced gut can lead to harmful states such as inflammation that can affect how the brain functions. 'A diet high in fibre, healthy fats such as omega-3s, and antioxidants helps good bacteria in our guts to thrive, whereas too much sugar, saturated fat, and other components of a highly processed diet could promote harmful bacteria and inflammation.' UniSC Senior Lecturer in Nutrition and Dietetics Dr Anthony Villani said the Mediterranean diet was under-researched in ADHD, with a lack of robust trials investigating dietary strategies in its management. 'Most research to date has focused on elimination diets, with very limited exploration of the Mediterranean diet,' Dr Villani said. 'We know from other studies that children and adolescents with ADHD – a common neurodevelopmental disorder characterised by symptoms of inattention, hyperactivity and impulsivity – tend to have poorer diets, compared to those without. 'These diets are often highly processed and at risk of being deficient in certain nutrients, including omega-3 fatty acids, iron, zinc, magnesium, vitamin D and B vitamins, known to support optimal brain functioning. 'Following a Mediterranean-based diet has great potential to help improve ADHD symptoms by improving gut health and lowering inflammation as it is rich in anti-inflammatory foods and fibre such as olive oil, fruits, vegetables and fish." While medications are the most common treatment for managing symptoms of ADHD, they are associated with side effects and many people do not respond effectively. 'While it's not a cure for ADHD, a Mediterranean-based diet, as well as targeted supplements, may help some people better regulate ADHD behaviours more effectively. It's a low-risk, affordable option worth considering,' Dr Villani said. The researchers recommend clinical trials to determine the clinical utility and effectiveness of the Mediterranean diet in ADHD management.
Scoop
a day ago
- Scoop
Ozempic And Wegovy: The Pros And Cons, Explained
Earlier this week semaglutide drugs Ozempic and Wegovy were made available for prescription in New Zealand. Semaglutide originally arrived on the market in the US in 2017 as a diabetes medication, but has quickly been tied to extreme weight loss. Wegovy can be prescribed to people over the age of 12, but many of the 65 percent of New Zealanders who are overweight or obese will have trouble affording it, with an estimated price of $500 a month. The drugs have transformed our ability to manage obesity and type 2 diabetes, and have shown potential for a wide range of conditions such as Alzheimer's, addiction and depression. But there are clouds to go along with the silver linings - such as potential vision loss. "This condition, it occurs when there's insufficient blood flow to the nerves connecting the eye to the brain, and this leads to damage," US-based health reporter for New Scientist, Grace Wade, told RNZ's Sunday Morning. The specific condition was non-arteritic anterior ischemic optic neuropathy. "That can cause this sudden and permanent vision loss, usually in just one eye. Now, I should be clear this isn't total vision loss, at least usually - it's more like cloudiness, stuff like that." People using semaglutides to treat diabetes were 4.3 times more likely to develop this condition, and those using it for weight loss 7.6 times, as people using other types of diabetes medications, a 2024 study found (Wade wrote about it in New Scientist here). The drugs work by suppressing appetite, which typically leads to weight loss as people consume fewer calories. But the weight lost was not always beneficial, Wade said. "It leads the body to break down fat, muscle and actually even bone for nutrients, and that's why… some research has found that upwards of 40 percent of the weight loss seen with these medications is due to loss of muscle mass… that makes it really important that people prioritise exercise when taking these drugs because if you don't use your muscle, you're more likely to lose it." Getting into the exercise habit was also important since one day, most people on Ozempic or Wegovy will stop taking it - putting themselves at risk of putting the weight back on if they were not regularly moving. Then there is 'Ozempic face'. "I don't think this is a clinical term yet, but it's something that's popped up a lot in social media," Wade said. "People who are taking these medications start developing... a sunken or hollowed out appearance, which can exacerbate fine lines and wrinkles, make their skin look a little more saggy. "It isn't clear exactly how common this is… but it probably has to do with just weight loss, right? If you're losing weight, as much as some people would want to target their weight loss to certain areas of their body, we can't really do that. So, you know, any sort of overall weight loss is also gonna cause a loss of fat in your face." There were also side effects for some, including constantly needing to go to the toilet, feeling bloated, belching, constipation, heartburn, fever, upset stomach - the list, collected here by the Mayo Clinic, goes on. And nearly half of people who try it make it through a three-month course, one study found. Wade also mentioned a lot of people taking semaglutide for diabetes or Alzheimer's prevention might be older and "frail", so not able to lose weight. "Drug developers are actually working to develop new drugs that have similar effects as these weight loss medications, but without the weight loss." The good news One unexpected benefit of semaglutide was its apparent effect on not just calorie consumption, but use of addictive substances, such as alcohol and nicotine. "We aren't exactly sure why that is, but it appears to be with how these medications affect brain activity. "So these drugs curb cravings for alcohol similar to how they curb cravings for food, right? And that probably has to do with their impact on brain regions involved in reward processing and craving… "A study of more than half-a-million people with a history of opioid use disorders showed that those who took Ozempic or similar [medications] had significantly lower rates of opioid overdose than those who didn't. "Other studies have shown similar effects in people with cannabis use disorder, cigarette smokers and alcoholism." Scientists did not expect this effect, calling it an "unintended consequence". The drugs have also shown promise in reducing heart attacks and strokes, improving fertility, treating pain, improving mental health, lower the risk of kidney failure and slowing cognitive decline. "I've never encountered a group of drugs like this," Wade said. "That's what makes these drugs so remarkable, because most medications can only treat one or two conditions, right?" She said it was likely that weight loss was playing a role - as it frequently does in health - but "it doesn't seem to be the only [reason]". But there is still a lot of research to be done, she said, before we all start taking it. "Let's unravel how they can treat all of these conditions before we jump the gun and start suggesting we, you know, maybe put it in everyone's water or something."
1News
3 days ago
- 1News
Delay-plagued convention centre to host medical conferences in 2026
The New Zealand International Convention Centre in Auckland will host two major medical conferences next year — after finally opening following a near six-year delay. A spokesperson for the convention centre, which was initially scheduled to open in 2020 but was delayed following a devastating fire, said both the Australian and New Zealand College of Anaesthetists and the Royal Australian and New Zealand College of Ophthalmologists would hold their conferences at the centre. The events would be held from April 30 to May 5 and November 5 and November 9, respectively. The convention centre would officially open in February next year. According to NZ Herald, nine other events had already been booked at the centre. It was expected both newly announced events would include a combined total of 3300 delegates, "generating millions of dollars in economic activity", according to a spokesperson for the centre. ADVERTISEMENT NZICC director of sales and planning, Alana Bicknell, said it was a "major boost" to secure two major conferences during the convention centre's first year of opening. 'We can't wait to extend our manaakitanga to the delegates of both conferences. We're confident the NZICC will absolutely wow them.' 'We appreciate the support from our industry partners to help bring these events to New Zealand, and also the government for their recent announcement regarding changes to the law around the advertising of medicines that have previously been a barrier to international medical conferences coming here,' Bicknell said. SkyCity, which owned the convention centre, filed legal proceedings against Fletcher Building and The Fletcher Construction Company, seeking compensation of $330 million for "ongoing delays" to the project. SkyCity said the project was nearly six and a half years behind the contractually agreed delivery date of January 2019. SkyCity claimed it was entitled to $330 million in liquidated damages from Fletchers under the contract. Fletcher Building said it would "vigorously" defend the legal action and had already paid "significant" liquidated damages to SkyCity over the delays.
